Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus

P. Sharma, Achyut K Bhattacharyya, H. S. Garewal, R. E. Sampliner

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background: Endoscopic reversal of Barrett's esophagus with multipolar electrocoagulation and high-dose omeprazole has been previously described but long-term results are not available. The aim of this study was to follow patients after endoscopic reversal and to perform a detailed analysis of the 'new' squamous mucosa. Methods: After reversal, patients with Barrett's esophagus were maintained on high-dose omeprazole and underwent interval endoscopy, and large biopsies were obtained of the former Barrett's epithelium. Results: Nine of 11 patients were men; the mean age was 62 years. The mean length of Barrett's mucosa was 4.4 cm; the mean dose of omeprazole used was 49 mg/day. All patients had an initial complete response to treatment - no evidence of Barrett's endoscopically and histologically. Three patients had intestinal metaplasia underlying the new squamous mucosa in the latest follow-up biopsies. In these 3 patients, only 0.4%, 2%, and 8% of the total biopsy area had intestinal metaplasia. All but 4 patients had underlying intestinal metaplasia at variable times during the study period. Patients have been followed for a mean of 36 months (range 19 to 53 months). Conclusions: New squamous mucosa is durable and resembles normal squamous tissue. Underlying glands of intestinal metaplasia are intermittently found. Because the significance of this residual intestinal metaplasia is unclear, surveillance endoscopy with biopsies of the treated segment is recommended even after reversal therapy.

Original languageEnglish (US)
Pages (from-to)159-164
Number of pages6
JournalGastrointestinal Endoscopy
Volume50
Issue number2
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Barrett Esophagus
Epithelium
Metaplasia
Omeprazole
Mucous Membrane
Biopsy
Endoscopy
Electrocoagulation
Intestinal Mucosa
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. / Sharma, P.; Bhattacharyya, Achyut K; Garewal, H. S.; Sampliner, R. E.

In: Gastrointestinal Endoscopy, Vol. 50, No. 2, 1999, p. 159-164.

Research output: Contribution to journalArticle

Sharma, P. ; Bhattacharyya, Achyut K ; Garewal, H. S. ; Sampliner, R. E. / Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. In: Gastrointestinal Endoscopy. 1999 ; Vol. 50, No. 2. pp. 159-164.
@article{243fd636791e40918d4e76fc143fc795,
title = "Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus",
abstract = "Background: Endoscopic reversal of Barrett's esophagus with multipolar electrocoagulation and high-dose omeprazole has been previously described but long-term results are not available. The aim of this study was to follow patients after endoscopic reversal and to perform a detailed analysis of the 'new' squamous mucosa. Methods: After reversal, patients with Barrett's esophagus were maintained on high-dose omeprazole and underwent interval endoscopy, and large biopsies were obtained of the former Barrett's epithelium. Results: Nine of 11 patients were men; the mean age was 62 years. The mean length of Barrett's mucosa was 4.4 cm; the mean dose of omeprazole used was 49 mg/day. All patients had an initial complete response to treatment - no evidence of Barrett's endoscopically and histologically. Three patients had intestinal metaplasia underlying the new squamous mucosa in the latest follow-up biopsies. In these 3 patients, only 0.4{\%}, 2{\%}, and 8{\%} of the total biopsy area had intestinal metaplasia. All but 4 patients had underlying intestinal metaplasia at variable times during the study period. Patients have been followed for a mean of 36 months (range 19 to 53 months). Conclusions: New squamous mucosa is durable and resembles normal squamous tissue. Underlying glands of intestinal metaplasia are intermittently found. Because the significance of this residual intestinal metaplasia is unclear, surveillance endoscopy with biopsies of the treated segment is recommended even after reversal therapy.",
author = "P. Sharma and Bhattacharyya, {Achyut K} and Garewal, {H. S.} and Sampliner, {R. E.}",
year = "1999",
doi = "10.1016/S0016-5107(99)70218-X",
language = "English (US)",
volume = "50",
pages = "159--164",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus

AU - Sharma, P.

AU - Bhattacharyya, Achyut K

AU - Garewal, H. S.

AU - Sampliner, R. E.

PY - 1999

Y1 - 1999

N2 - Background: Endoscopic reversal of Barrett's esophagus with multipolar electrocoagulation and high-dose omeprazole has been previously described but long-term results are not available. The aim of this study was to follow patients after endoscopic reversal and to perform a detailed analysis of the 'new' squamous mucosa. Methods: After reversal, patients with Barrett's esophagus were maintained on high-dose omeprazole and underwent interval endoscopy, and large biopsies were obtained of the former Barrett's epithelium. Results: Nine of 11 patients were men; the mean age was 62 years. The mean length of Barrett's mucosa was 4.4 cm; the mean dose of omeprazole used was 49 mg/day. All patients had an initial complete response to treatment - no evidence of Barrett's endoscopically and histologically. Three patients had intestinal metaplasia underlying the new squamous mucosa in the latest follow-up biopsies. In these 3 patients, only 0.4%, 2%, and 8% of the total biopsy area had intestinal metaplasia. All but 4 patients had underlying intestinal metaplasia at variable times during the study period. Patients have been followed for a mean of 36 months (range 19 to 53 months). Conclusions: New squamous mucosa is durable and resembles normal squamous tissue. Underlying glands of intestinal metaplasia are intermittently found. Because the significance of this residual intestinal metaplasia is unclear, surveillance endoscopy with biopsies of the treated segment is recommended even after reversal therapy.

AB - Background: Endoscopic reversal of Barrett's esophagus with multipolar electrocoagulation and high-dose omeprazole has been previously described but long-term results are not available. The aim of this study was to follow patients after endoscopic reversal and to perform a detailed analysis of the 'new' squamous mucosa. Methods: After reversal, patients with Barrett's esophagus were maintained on high-dose omeprazole and underwent interval endoscopy, and large biopsies were obtained of the former Barrett's epithelium. Results: Nine of 11 patients were men; the mean age was 62 years. The mean length of Barrett's mucosa was 4.4 cm; the mean dose of omeprazole used was 49 mg/day. All patients had an initial complete response to treatment - no evidence of Barrett's endoscopically and histologically. Three patients had intestinal metaplasia underlying the new squamous mucosa in the latest follow-up biopsies. In these 3 patients, only 0.4%, 2%, and 8% of the total biopsy area had intestinal metaplasia. All but 4 patients had underlying intestinal metaplasia at variable times during the study period. Patients have been followed for a mean of 36 months (range 19 to 53 months). Conclusions: New squamous mucosa is durable and resembles normal squamous tissue. Underlying glands of intestinal metaplasia are intermittently found. Because the significance of this residual intestinal metaplasia is unclear, surveillance endoscopy with biopsies of the treated segment is recommended even after reversal therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032787931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032787931&partnerID=8YFLogxK

U2 - 10.1016/S0016-5107(99)70218-X

DO - 10.1016/S0016-5107(99)70218-X

M3 - Article

C2 - 10425406

AN - SCOPUS:0032787931

VL - 50

SP - 159

EP - 164

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 2

ER -